心房颤动对omecamtiv mecarbil在心力衰竭中疗效与安全性的影响:GALACTIC-HF试验
GALACTIC-HF试验探索心房颤动/扑动(AFF)对omecamtiv mecarbil疗效的影响。结果显示,基线AFF患者(n=2245,27%)从omecamtiv mecarbil治疗中获益少于无AFF患者(交互P=0.012),且这种疗效减弱在使用地高辛的AFF患者中更为显著(交互P=0.007)。
要点
- 基线AFF患者从omecamtiv mecarbil治疗中获益少于无AFF患者(交互P=0.012)。
- AFF对疗效的减弱在使用地高辛的患者中显著更明显(交互P=0.007)。
- 未使用地高辛(P=0.47)或无AFF的地高辛使用者中未见明显效应修饰。
核心结论
- 基线AFF患者从omecamtiv mecarbil治疗中获益少于无AFF患者,且疗效减弱主要集中于同时使用地高辛的AFF患者。
研究设计与样本
- GALACTIC-HF试验纳入NYHA II-IV级、左心室射血分数≤35%且利钠肽升高的心力衰竭患者。
- AFF为预设亚组,评估其对主要和次要结局治疗效应的影响,并探索地高辛使用与否的效应修饰。
主要发现
- AFF患者(n=2245,27%)年龄更大、更多为住院 randomization、缺血性病因或心肌梗死史较少、NYHA分级更差、生活质量更差、eGFR更低、NT-proBNP更高。
- omecamtiv mecarbil的治疗效应受基线AFF修饰(交互P=0.012),无AFF患者获益更大。
- AFF对治疗效应的减弱在地高辛使用者中显著更明显(交互P=0.007);未使用地高辛者(P=0.47)或无AFF的地高辛使用者中效应修饰证据极少。
临床怎么用
- 对于基线存在AFF的心力衰竭患者,使用omecamtiv mecarbil的获益可能减弱,尤其是同时使用地高辛者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: In GALACTIC-HF, the cardiac myosin activator omecamtiv mecarbil compared with placebo reduced the risk of heart failure events or cardiovascular death in patients with heart failure with reduced ejection fraction. We explored the influence of atrial fibrillation or flutter (AFF) on the effectiveness of omecamtiv mecarbil. METHODS AND RESULTS: GALACTIC-HF enrolled patients with New York Heart Association (NYHA) Class II-IV heart failure, left ventricular ejection fraction ≤35%, and elevated natriuretic peptides. We assessed whether the presence or absence of AFF, a pre-specified subgroup, modified the treatment effect for the primary and secondary outcomes, and additionally explored effect modification in patients who were or were not receiving digoxin. Patients with AFF (n = 2245, 27%) were older, more likely to be randomized as an inpatient, less likely to have a history of ischaemic aetiology or myocardial infarction, had a worse NYHA class, worse quality of life, lower estimated glomerular filtration rate, and higher N-terminal pro-B-type natriuretic peptide. The treatment effect of omecamtiv mecarbil was modified by baseline AFF (interaction P = 0.012), with patients without AFF at baseline deriving greater benefit. The worsening of the treatment effect by baseline AFF was significantly more pronounced in digoxin users than in non-users (interaction P = 0.007); there was minimal evidence of effect modification in those patients not using digoxin (P = 0.47) or in digoxin users not in AFF. CONCLUSION: Patients in AFF at baseline were less likely to benefit from omecamtiv mecarbil than patients without AFF, although the attenuation of the treatment effect was disproportionally concentrated in patients with AFF who were also receiving digoxin.Clinical Trial Registration: NCT02929329.
引用
- Solomon, Claggett, Miao, et al. Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. Eur Heart J. 2022. PMID: 35325102. doi:10.1093/eurheartj/ehac144
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。